BRIACELL THERAPEUTICS CORP. Income (Loss) from Continuing Operations before Income Taxes, Domestic
BRIACELL THERAPEUTICS CORP. (BCTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $24.00 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-16.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2025-10-16
- BRIACELL THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $24.00M.
- BRIACELL THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$23.95M, a 1069.51% decline from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $2.47M.
- BRIACELL THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$16.56M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-07-31 | $24.00M 10-K · filed 2025-10-16 | |
| 2024-07-31 | -$23.95M 10-K · filed 2025-10-16 | |
| 2023-07-31 | $2.47M 10-K · filed 2024-10-29 | |
| 2022-07-31 | -$16.56M 10-K · filed 2023-10-25 | -$16.55M 10-K · filed 2022-10-28 |
| 2021-07-31 | -$11.43M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |